Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/cod.12988 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Five Cases of Non-radiographic Spondyloarthritis (nr-SpA) of Patients from a Tertiary Care Center in the Philippines: A Case Series.
Acta Med Philipp
November 2024
Department of Medicine, Makati Medical Center.
Axial Spondyloarthritis (SpA) is a chronic inflammatory disease of the spine associated with the gene HLA-B27. Non-radiographic spondyloarthritis (nr-SpA), an early stage of axial SpA often goes unrecognized in many settings including the Philippines. We describe five Filipinos from a tertiary health care facility who fulfill the Assessment of SpondyloArthritis International Society (ASAS) 2009 criteria for non-radiographic SpA with the aim of increasing awareness of this disease in the Philippines.
View Article and Find Full Text PDFAdvances in the management of psoriatic arthritis in adults.
BMJ
November 2024
University of Toronto, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, ON, Canada
Article Synopsis
- * Management starts with assessing the patient's skin and joints while screening for other health issues, followed by a mix of therapies like education, lifestyle changes, and physiotherapy.
- * Treatment options include non-steroidal anti-inflammatory drugs and disease-modifying therapies such as methotrexate and biologics, but there’s a need for better biomarkers to personalize these treatments for each patient.
Authors' Reply to Wang et al., "Comment on 'Efficacy and Safety of Brodalumab, an Anti‑interleukin‑17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16‑Week Results of a Randomized Clinical Trial'".
Am J Clin Dermatol
November 2024
Division of Dermatological Science, Department of Dermatology, Nihon University School of Medicine, 30-1, Oyaguchikamicho, Itabashi-ku, Tokyo, 173-8610, Japan.
Biologic anti-IL17 drugs in erythrodermic psoriasis.
JAAD Int
September 2024
Dermatology Clinic, Department Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Background: Erythrodermic psoriasis (EP) is a potentially life-threatening disease, and there is currently no consensus regarding its optimal treatment. Biological drugs approved for Psoriasis Vulgaris treatment have been used as alternatives to traditional medications.
Objective: To evaluate the clinical response and tolerability of anti- interleukin 17 (IL17) biologic drugs during a 2-year-follow-up.
Efficacy and Safety of Brodalumab, an Anti-interleukin-17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16-Week Results of a Randomized Clinical Trial.
Am J Clin Dermatol
September 2024
Division of Dermatological Science, Department of Dermatology, Nihon University School of Medicine, 30-1, Oyaguchikamicho, Itabashi-ku, Tokyo, 173-8610, Japan.
Article Synopsis
- Palmoplantar pustulosis (PPP) is a chronic skin condition causing non-infectious pustules on the palms and soles, and brodalumab, an anti-interleukin-17 monoclonal antibody, is being studied as a potential treatment.
- A phase 3 trial in Japan involved patients aged 18-70 with moderate to severe PPP, assessing the safety and effectiveness of brodalumab compared to a placebo over 16 weeks.
- Results showed significant improvement in disease scores for those receiving brodalumab, with a greater reduction in symptoms compared to the placebo, indicating its potential as an effective therapy for PPP.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!